Tereos Syral Submits ‘Intestinal Comfort’ Health Claim to EFSA for SCFOS
Used for more than twenty years as food ingredients in Europe and even more in Japan, scFOS are supported by more than 150 scientific studies demonstrating their health benefits and mechanisms of action.
17 May 2012 --- On the basis of new proprietary scientific evidence, Tereos Syral has worked for more than one year on building a dossier to demonstrate the effect of fructo-oligosaccharides from sucrose (scFOS) on the reduction of intestinal discomfort from 4 weeks of consumption.
Taking into account the recommendations made by EFSA’s Panel on Dietetic Products Nutrition and Allergies (NDA) after the process of evaluation of all the Article 13.1 health claims, Tereos Syral firmly believes that there is scope to support a specific health claim on fructo-oligosaccharides from sucrose on this health relationship via Article 13.5. The request is registered under the number EFSA-Q-2012-00537 on EFSA’s website.
Used for more than twenty years as food ingredients in Europe and even more in Japan, scFOS are supported by more than 150 scientific studies demonstrating their health benefits and mechanisms of action. Fructo-oligosaccharides are also commonly used in infant and follow-on formulae in Japan and Europe. Furthermore they already benefit from official recognition as safe and healthy ingredients with both GRAS (USA) and FOSHU (Japan) status.
Tereos is a major player in the production of scFOS from sucrose in Europe, with a dedicated and state-of-art plant in the North of Paris.
